Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACADNASDAQ:CYTKNASDAQ:NTLANASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$21.58-1.2%$16.20$13.40▼$25.23$3.61B0.471.93 million shs979,313 shsCYTKCytokinetics$30.81-1.6%$38.12$29.31▼$61.38$3.67B0.811.69 million shs568,904 shsNTLAIntellia Therapeutics$9.47+2.9%$7.99$5.90▼$28.18$977.31M2.332.55 million shs1.80 million shsSRPTSarepta Therapeutics$38.99-2.6%$56.56$34.10▼$173.25$3.83B0.851.77 million shs2.22 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+0.74%+27.33%+51.95%+7.29%+43.09%CYTKCytokinetics-4.13%+4.37%-17.45%-38.75%-47.94%NTLAIntellia Therapeutics-4.86%+16.75%+16.16%-24.90%-64.22%SRPTSarepta Therapeutics+0.15%+12.06%-27.49%-63.06%-68.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals3.2822 of 5 stars3.32.00.00.03.34.21.3CYTKCytokinetics4.1551 of 5 stars4.51.00.04.63.80.80.0NTLAIntellia Therapeutics4.632 of 5 stars4.31.00.04.73.82.51.3SRPTSarepta Therapeutics4.8254 of 5 stars4.42.00.04.23.92.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.64Moderate Buy$26.8324.34% UpsideCYTKCytokinetics 2.94Moderate Buy$74.44141.57% UpsideNTLAIntellia Therapeutics 2.67Moderate Buy$36.90289.86% UpsideSRPTSarepta Therapeutics 2.83Moderate Buy$122.61214.43% UpsideCurrent Analyst Ratings BreakdownLatest NTLA, CYTK, ACAD, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$40.00 ➝ $40.005/21/2025ACADACADIA PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Buy$20.00 ➝ $35.005/20/2025ACADACADIA PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $24.005/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/20/2025SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$169.00 ➝ $84.005/19/2025ACADACADIA PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $31.005/19/2025ACADACADIA PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.005/19/2025ACADACADIA PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$26.00 ➝ $26.005/19/2025ACADACADIA PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$24.00 ➝ $28.005/19/2025ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $30.005/19/2025ACADACADIA PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $32.00(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$996.28M3.63N/AN/A$2.63 per share8.21CYTKCytokinetics$19.22M191.49N/AN/A($3.94) per share-7.82NTLAIntellia Therapeutics$45.57M21.51N/AN/A$11.73 per share0.81SRPTSarepta Therapeutics$2.23B1.72N/AN/A$9.19 per share4.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals-$61.29M$1.3727.6328.40N/A13.83%25.83%14.71%8/5/2025 (Estimated)CYTKCytokinetics-$526.24M-$5.29N/AN/AN/A-17,906.25%N/A-50.21%N/ANTLAIntellia Therapeutics-$481.19M-$5.23N/AN/AN/AN/A-49.34%-40.27%N/ASRPTSarepta Therapeutics-$535.98M-$2.6931.143.56N/A7.43%11.00%3.35%8/6/2025 (Estimated)Latest NTLA, CYTK, ACAD, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million2/27/2025Q4 2024CYTKCytokinetics-$1.29-$1.26+$0.03-$1.26$14.26 million$16.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.292.11CYTKCytokinetics5.939.289.28NTLAIntellia TherapeuticsN/A6.736.73SRPTSarepta Therapeutics0.933.843.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%CYTKCytokineticsN/ANTLAIntellia Therapeutics88.77%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%CYTKCytokinetics2.70%NTLAIntellia Therapeutics3.10%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million119.30 millionOptionableCYTKCytokinetics250119.43 million114.00 millionOptionableNTLAIntellia Therapeutics600103.58 million98.59 millionOptionableSRPTSarepta Therapeutics84098.28 million88.17 millionOptionableNTLA, CYTK, ACAD, and SRPT HeadlinesRecent News About These CompaniesFDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne studyMay 22 at 11:41 AM | biopharmadive.comSarepta Can Start Dosing Elevidys Trial, UK Regulators SayMay 22 at 11:41 AM | precisionmedicineonline.comSarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study ContinueMay 21 at 3:37 PM | marketwatch.comSarepta, Roche get U.K. feedback to lift clinical hold on Elevidys' Duchenne trialMay 21 at 3:37 PM | msn.comSarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in DuchenneMay 21 at 3:37 PM | finance.yahoo.comSarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular DystrophyMay 21 at 9:08 AM | businesswire.comVestal Point Capital LP Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 21 at 8:14 AM | marketbeat.comTriglav Skladi D.O.O. Invests $1.34 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 21 at 6:55 AM | marketbeat.comNuveen Asset Management LLC Increases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 21 at 4:55 AM | marketbeat.comSarepta Shares Higher After J.P. Morgan NoteMay 20 at 4:11 PM | marketwatch.comSRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative DelaysMay 20 at 8:24 AM | msn.comSummit Partners Public Asset Management LLC Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 19 at 7:41 AM | marketbeat.comSuvretta Capital Management LLC Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 19 at 7:41 AM | marketbeat.comRafferty Asset Management LLC Sells 28,806 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 19 at 6:13 AM | marketbeat.comSphera Funds Management LTD. Has $12.03 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 18, 2025 | marketbeat.comSarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of TreatmentMay 16, 2025 | finance.yahoo.comNovartis, Sarepta tipped to drive genomic therapy sales toward $90BMay 15, 2025 | fiercepharma.comOrbimed Advisors LLC Sells 41,100 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 15, 2025 | marketbeat.comBearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimatesMay 14, 2025 | finance.yahoo.comPharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore (SRPT)May 14, 2025 | marketbeat.comEnsign Peak Advisors Inc Has $21.10 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNTLA, CYTK, ACAD, and SRPT Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$21.58 -0.27 (-1.23%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Cytokinetics NASDAQ:CYTK$30.81 -0.50 (-1.58%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Intellia Therapeutics NASDAQ:NTLA$9.46 +0.27 (+2.88%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$38.99 -1.06 (-2.64%) As of 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1 Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith? Microsoft Could Rally as EU Antitrust Case Nears Resolution Canada Goose Soars 30%—Is This Rally Built to Last? Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum 5 Reasons You Will Be Glad You Bought Target in 2025 Moderna Stock Looks Ripe for a Short Squeeze Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
